ABT 888

Known as: ABT-888, ABT888, PARP-1 inhibitor ABT-888 
A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
PURPOSE Little is known about the optimal clinical use of ABT-888 (veliparib) for treatment of glioblastoma. ABT-888 is a PARP… (More)
  • table I
Is this relevant?
2013
2013
BACKGROUND The cytotoxicity of radiotherapy and chemotherapy can be enhanced by modulating DNA repair. PARP is a family of… (More)
  • figure 1
Is this relevant?
2013
2013
PURPOSE Poly(ADP-ribose) polymerase plays a critical role in the recognition and repair of DNA single-strand breaks and double… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Small-molecule inhibitors of PARP are thought to mediate their antitumor effects as catalytic inhibitors that block repair of DNA… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
A phase I trial of ABT-888 (veliparib), a PARP inhibitor, in combination with topotecan, a topoisomerase I-targeted agent, was… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE ABT-888, currently in phase 2 trials, is a potent oral poly(ADP-ribose) polymerase inhibitor that enhances the activity… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
The chemo- and radioresponse of tumor cells can be determined by genetic factors (e.g., those that modify cell cycle arrest, DNA… (More)
  • figure 1
  • figure 3
  • table 1
  • table 2
Is this relevant?
2008
2008
ABT-888 is a potent, orally bioavailable PARP-1/2 inhibitor shown to potentiate DNA damaging agents. The ability to potentiate… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE To evaluate the preclinical pharmacokinetics and antitumor efficacy of a novel orally bioavailable poly(ADP-ribose… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?